Management of Newly Detected Atrial Fibrillation: A Clinical Practice Guideline from the American Academy of Family Physicians and the American College of Physicians

Annals of Internal Medicine

Volumn 139, Issue 12, 2003, Pages

  Snow, Vincenza ^a   Weiss, Kevin B ^b   LeFevre, Michael ^b   McNamara, Robert ^b   Bass, Eric ^b   Green, Lee A ^b   Michl, Keith ^b   Owens, Douglas K ^b   Susman, Jeffrey ^b   Allen, Deborah I ^b   Mottur Pilson, Christel ^b  

^a AMERICAN COLLEGE OF PHYSICIANS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ATENOLOL; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; FLECAINIDE; IBUTILIDE; METOPROLOL; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; VERAPAMIL; WARFARIN;

AMERICAN ACADEMY OF FAMILY PHYSICIANS; AMERICAN COLLEGE OF PHYSICIANS; ANTICOAGULANT THERAPY; CARDIOVERSION; CLINICAL TRIAL; DIRECT CURRENT CARDIOVERSION; DRUG CONTRAINDICATION; DRUG EFFICACY; EVIDENCE BASED MEDICINE; GENERAL PRACTITIONER; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HEART LEFT ATRIUM SIZE; HEART RATE; HEART RATE CONTROL; HEART RHYTHM; HEART RHYTHM CONTROL; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INTERNAL MEDICINE; LUNG TOXICITY; MAINTENANCE THERAPY; MEDICAL SOCIETY; MEDICAL SPECIALIST; PATIENT SELECTION; PHARMACOLOGICAL CARDIOVERSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINUS RHYTHM; STROKE; TORSADE DES POINTES; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

EID: 10744220379     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-139-12-200312160-00011     Document Type: Review

References (57)

1. Fuster V, Rydén LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol. 2001;38:1231-66. [PMID: 11583910]
2. McNamara RL, Tamariz LJ, Segal JS, Bass EB. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med. 2003;139:1018-33.
3. McNamara RL, Bass EB, Miller MR, Segal JB, Goodman SN, Kim NL, et al. Evidence Report on Management of New Onset Atrial Fibrillation. Agency for Healthcare Research and Quality publication no. AHRQ 01-E026. Rockville, MD: Agency for Healthcare Research and Quality; January 2001.
4. Guyatt G, Sinclair J, Cook D, Jaeschke R, Schunemann, H, Pauker S. Moving from Evidence to Action: Grading Recommendations-A Qualitative Approach. Users Guide to the Medical Literature. Chicago, IL: American Med Assoc; 2002.
5. Falk RH. Management of atrial fibrillation-radical reform or modest modification? [Editorial]. N Engl J Med. 2002;347:1883-4. [PMID: 12466514]
6. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-33. [PMID: 12466506]
7. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-40. [PMID: 12466507]
8. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356:1789-94. [PMID: 11117910]
9. Intervention strategies in the treatment of atrial fibrillation. Proceedings of an international symposium. Dresden, Germany, March 19-20, 1999. Thorac Cardiovasc Surg. 1999; 47 Suppl 3:333-87. [PMID: 10520762]
10. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med. 1990;323:1505-11. [PMID: 2233931]
11. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet. 1993;342:1255-62. [PMID: 7901582]
12. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687-91. [PMID: 7907677]
13. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633-8. [PMID: 8782752]
14. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;1:175-9. [PMID: 2563096]
15. Gulløv AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med. 1998;158:1513-21. [PMID: 9679792]
16. Morocutti C, Amabile G, Fattapposta F, Nicolosi A, Matteoli S, Trappolini M, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke. 1997;28:1015-21. [PMID: 9158644]
17. Harenberg J, Weuster B, Pfitzer M, Dempfle CE, Stehle G, Kubler W, et al. Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin. Semin Thromb Hemost. 1993;19 Suppl 1:116-21. [PMID: 8395713]
18. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gomick CC, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med. 1992;327:1406-12. [PMID: 1406859]
19. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18:349-55. [PMID: 1856403]
20. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991;84:527-39. [PMID: 1860198]
21. Hellemons BS, Langenberg M, Lodder J, Vermeer F, Schouten HJ, Lemmens T, et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ. 1999;319:958-64. [PMID: 10514159]
22. Pengo V, Zasso A, Barbero F, Banzato A, Nante G, Parissenti L, et al. Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. Am J Cardiol. 1998;82: 433-7. [PMID: 9723629]
23. Posada IS, Barriales V. Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. Am Heart J. 1999;138:137-43. [PMID: 10385777]
24. Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke. 2000;31:817-21. [PMID: 10753981]
25. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-70. [PMID: 11401607]
26. Lewis RV, Laing E, Moreland TA, Service E, McDevitt DG. A comparison of digoxin, diltiazem and their combination in the treatment of atrial fibrillation. Eur Heart J. 1988;9:279-83. [PMID: 3289931]
27. Falk RH, Knowlton AA, Bernard SA, Gotlieb NE, Battinelli NJ. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial. Ann Intern Med. 1987;106:503-6. [PMID: 3548521]
28. Wong CK, Lau CP, Leung WH, Cheng CH. Usefulness of labetalol in chronic atrial fibrillation. Am J Cardiol. 1990;66:1212-5. [PMID: 2239725]
29. Jordaens L, Trouerbach J, Calle P, Tavernier R, Derycke E, Vertongen P, et al. Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo. Eur Heart J. 1997;18:643-8. [PMID: 9129896]
30. Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Eur Heart J. 1997;18:649-54. [PMID: 9129897]
31. Koh KK, Kwon KS, Park HB, Baik SH, Park SJ, Lee KH, et al. Efficacy and safety of digoxin alone and in combination with low-dose diltiazem or betaxolol to control ventricular rate in chronic atrial fibrillation. Am J Cardiol. 1995;75:88-90. [PMID: 7801876]
32. Ang EL, Chan WL, Cleland JG, Moore D, Krikler SJ, Alexander ND, et al. Placebo controlled trial of xamoterol versus digoxin in chronic atrial fibrillation. Br Heart J. 1990;64:256-60. [PMID: 1977430]
33. Goldenberg IF, Lewis WR, Dias VC, Heywood JT, Pedersen WR. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure. Am J Cardiol. 1994;74:884-9. [PMID: 7977118]
34. Ellenbogen KA, Dias VC, Plumb VJ, Heywood JT, Mirvis DM. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study. J Am Coll Cardiol. 1991;18:891-7. [PMID: 1894861]
35. Salerno DM, Dias VC, Kleiger RE, Tschida VH, Sung RJ, Sami M, et al. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. The Diltiazem-Atrial Fibrillation/Flurter Study Group. Am J Cardiol. 1989;63:1046-51. [PMID: 2650517]
36. Lewis RV, Irvine N, McDevitt DG. Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem. Eur Heart J. 1988;9:777-81. [PMID: 3169046]
37. Lundström T, Rydén L. Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of dutiazem and verapamil. J Am Coll Cardiol. 1990;16:86-90. [PMID: 2358610]
38. Lundström T, Moor E, Rydén L. Differential effects of xamoterol and verapamil on ventricular rate regulation in patients with chronic atrial fibrillation. Am Heart J. 1992;124:917-23. [PMID: 1356311]
39. Lewis RV, McMurray J, McDevitt DG. Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. J Cardiovasc Pharmacol. 1989;13:1-6. [PMID: 2468920]
40. Panidis IP, Morganroth J, Baessler C. Effectiveness and safety of oral verapamil to control exercise-induced tachycardia in patients with atrial fibrillation receiving digitalis. Am J Cardiol. 1983;52:1197-201. [PMID: 6359848]
41. Schreck DM, Rivera AR, Tricarico VJ. Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intravenous digoxin. Ann Emerg Med. 1997;29:135-40. [PMID: 8998092]
42. Lewis RV, Irvine N, McDevitt DG. Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem. Eur Heart J. 1988;9:777-81. [PMID: 3169046]
43. Lewis RV, Laing E, Moreland TA, Service E, McDevitt DG. A comparison of digoxin, diltiazem and their combination in the treatment of atrial fibrillation. Eur Heart J. 1988;9:279-83. [PMID: 3289931]
44. Pomfret SM, Beasley CR, Challenor V, Holgate ST. Relative efficacy of oral verapamil and digoxin alone and in combination for the treatment of patients with chronic atrial fibrillation. Clin Sci (Lond). 1988;74:351-7. [PMID: 3281786]
45. Ahuja RC, Sinha N, Saran RK, Jain AK, Hasan M. Digoxin or verapamil or metoprolol for heart rate control in patients with mitral stenosis-a randomised cross-over study. Int J Cardiol. 1989;25:325-31. [PMID: 2613380]
46. Botto GL, Bonini W, Broffoni T. Modulation of ventricular rate in permanent atrial fibrillation: randomized, crossover study of the effects of slow-release formulations of gallopamil, dildazem, or verapamil. Clin Cardiol. 1998;21:837-40. [PMID: 9825197]
47. Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol. 1999;33:304-10. [PMID: 9973007]
48. Channer KS, James MA, MacConnell T, Rees JR. Beta-adrenoceptor blockers in atrial fibrillation: the importance of partial agonist activity. Br J Clin Pharmacol. 1994;37:53-7. [PMID: 7908532]
49. Ahuja RC, Sinha N, Saran RK, Jain AK, Hasan M. Digoxin or verapamil or metoprolol for heart rate control in patients with mitral stenosis-a randomised cross-over study. Int J Cardiol 1989;25:325-31. [PMID: 2613380]
50. Sweany AE, Moncloa F, Vickers FF, Zupkis RV. Antiarrhythmic effects of intravenous timolol in supraventricular arrhythmias. Clin Pharmacol Ther. 1985; 37:124-7. [PMID: 3881206]
51. Myers J, Atwood JE, Sullivan M, Forbes S, Friis R, Pewen W, et al. Perceived exertion and gas exchange after calcium and beta-blockade in atrial fibrillation. J Appl Physiol. 1987;63:97-104. [PMID: 2887542]
52. Lawson-Matthew PJ, McLean KA, Dent M, Austin CA, Channer KS. Xamoterol improves the control of chronic atrial fibrillation in elderly patients. Age Ageing. 1995;24:321-5. [PMID: 7484490]
53. Lin SK, Morganroth J, Heng M, Rubler S, Baird W, Atwood JE, et al. Effect of orally administered celiprolol in patients with chronic atrial fibrillation. J Cardiovasc Pharmacol. 1986;8 Suppl 4:S112-5. [PMID: 2427838]
54. Koh KK, Song JH, Kwon KS, Park HB, Baik SH, Park YS, et al. Comparative study of efficacy and safety of low-dose diltiazem or betaxolol in combination with digoxin to control ventricular rate in chronic atrial fibrillation: randomized crossover study. Int J Cardiol. 1995;52:167-74. [PMID: 8749878]
55. DiBianco R, Morganroth J, Freitag JA, Ronan JA Jr, Lindgren KM, Donohue DJ, et al. Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin. Am Heart J. 1984;108:1121-7. [PMID: 6148872]
56. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344:1411-20. [PMID: 11346805]
57. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000;342:913-20. [PMID: 10738049]